Proteomics International Laboratories, a pioneer in precision diagnostics, has announced the launch of its first-in-class predictive test for diabetic kidney disease, PromarkerD, in Australia. 

PromarkerD is a clinically validated blood test that can predict the risk of developing chronic kidney disease (DKD) in type 2 diabetes patients up to four years before clinical symptoms appear. This early warning provides healthcare professionals with a critical window to intervene, enabling better patient management and reducing the risk of severe kidney complications, including kidney failure and the need for dialysis or transplant.